170 results
Search Results
2. Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases
3. Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer
4. Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2 + Breast Cancer
5. IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target
6. Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
7. Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO
8. The expression of O-linked glycosyltransferase GALNT7 in breast cancer is dependent on estrogen-, progesterone-, and HER2-receptor status, with prognostic implications
9. Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer
10. The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer
11. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
12. Anti-HER2 scFv Expression in Escherichia coli SHuffle®T7 Express Cells: Effects on Solubility and Biological Activity
13. The Evolving Landscape of HER2-Directed Breast Cancer Therapy
14. Evaluation of homodimer 99mTc-HYNIC-E(SSSLTVPWY)2 peptide on HER2-over expressed breast cancer cells
15. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer
16. Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment
17. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization
18. Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer
19. Current Treatment Options for Breast Cancer Brain Metastases
20. DNA methylation marker to estimate the breast cancer cell fraction in DNA samples
21. Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009–2016: a cross-sectional study
22. Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions
23. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer
24. The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review
25. Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
26. SLC35A2 expression is associated with HER2 expression in breast cancer
27. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies
28. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval
29. Crizotinib induced antitumor activity and synergized with chemotherapy and hormonal drugs in breast cancer cells via downregulating MET and estrogen receptor levels
30. HER2 fluorescent in situ hybridization signal degradation: a 10-year retrospective study
31. The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype
32. Effect of level of hormone-receptor expression on treatment outcomes of “triple-positive” early-stage breast cancer
33. Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer
34. Changes in Citric Acid Cycle and Nucleoside Metabolism Are Associated with Anthracycline Cardiotoxicity in Patients with Breast Cancer
35. A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women
36. HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
37. Paget’s disease of the nipple in a Her2-positive breast cancer xenograft model
38. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor
39. Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial
40. Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
41. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1)
42. Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases
43. Loss of HER2 after HER2-targeted treatment
44. Application of the D492 Cell Lines to Explore Breast Morphogenesis, EMT and Cancer Progression in 3D Culture
45. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
46. Molecular subtypes of screen-detected breast cancer
47. Applying the New Guidelines of HER2 Testing in Breast Cancer
48. Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition
49. Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors
50. Search of MicroRNAs Regulating the Receptor Status of Breast Cancer In Silico and Experimental Confirmation of Their Expression in Tumors
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.